HBV reactivation (HBVr) is a well-known complication of immunosuppressive (IS) treatment. The aim of this study was to evaluate the awareness of rheumatologists about the risk of HBVr. A survey was sent via e-mail to 270 members of the Turkish Society for Rheumatology. It consisted of fourteen questions on their awareness of the major society guidelines, approach to hepatitis B virus (HBV) screening according to different IS regimens, decision process in screening patients for HBV, knowledge of antiviral treatments for HBV, follow-up strategies, experience and postgraduate training on HBVr. Forty-eight (17.8%) rheumatologists responded to the survey. Of the respondents, 93.8% reported that they screened all patients before IS treatment, while 6.2% screened patients with a high risk of HBV infection only. The screening rate was 95.8% (46/48) in patients undergoing high-risk IS treatment and 35.4% (17/48) in those undergoing low-risk treatment. All respondents screened for HBsAg, and 83.3% (40/48) screened for anti-HBc IgG and anti-HBs. Forty-four (91.7%) rheumatologists had previously initiated antiviral prophylaxis, and 14 (29.2%) had detected HBVr in at least one patient. Rheumatologists had a high awareness of the necessity for HBV screening before IS treatment. However, the screening rates were still lower than desired, especially in patients receiving IS treatments with moderate or low risk of reactivation.

中文翻译：

---

风湿病学家对免疫抑制治疗前乙型肝炎的重新认识。

HBV激活（HBVr）是免疫抑制（IS）治疗的众所周知的并发症。这项研究的目的是评估风湿病学家对HBVr风险的认识。通过电子邮件将调查发送给土耳其风湿病学会的270名成员。它由14个问题组成，这些问题涉及他们对主要社会准则的认识，根据不同IS方案进行乙肝病毒（HBV）筛查的方法，对HBV进行患者筛查的决策程序，对HBV的抗病毒治疗知识，后续策略，经验和HBVr的研究生培训。48名（17.8％）风湿病学家对调查做出了回应。在受访者中，有93.8％的人报告说他们在IS治疗之前对所有患者进行了筛查，而6.2％的人仅对具有HBV感染高风险的患者进行了筛查。筛查率为95。接受高危IS治疗的患者为8％（46/48），接受低危治疗的患者为35.4％（17/48）。所有受访者均筛查了HBsAg，83.3％（40/48）筛查了抗HBc IgG和抗HBs。四十四（91.7％）名风湿病医生先前曾进行过抗病毒治疗，至少有一名患者中有14名（29.2％）检出了HBVr。风湿病学家对在IS治疗之前进行HBV筛查的必要性有很高的认识。但是，筛查率仍低于期望值，尤其是在接受中度或低度再激活风险的IS治疗的患者中。7％的风湿病医生以前曾进行过抗病毒治疗，并且至少有14名患者（29.2％）检测到了HBVr。风湿病学家对在IS治疗之前进行HBV筛查的必要性有很高的认识。但是，筛查率仍低于期望值，尤其是在接受中度或低度再激活风险的IS治疗的患者中。7％的风湿病医生以前曾进行过抗病毒治疗，并且至少有14名患者（29.2％）检测到了HBVr。风湿病学家对IS治疗前进行HBV筛查的必要性高度了解。但是，筛查率仍低于期望值，尤其是在接受中度或低度再激活风险的IS治疗的患者中。